AR040654A1 - Aditivos a base de acidos polialquilenglicolicos - Google Patents

Aditivos a base de acidos polialquilenglicolicos

Info

Publication number
AR040654A1
AR040654A1 AR20030102624A ARP030102624A AR040654A1 AR 040654 A1 AR040654 A1 AR 040654A1 AR 20030102624 A AR20030102624 A AR 20030102624A AR P030102624 A ARP030102624 A AR P030102624A AR 040654 A1 AR040654 A1 AR 040654A1
Authority
AR
Argentina
Prior art keywords
hydrogen
conjugates
acids
polyalkylene glycol
integer value
Prior art date
Application number
AR20030102624A
Other languages
English (en)
Spanish (es)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR040654A1 publication Critical patent/AR040654A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/337Polymers modified by chemical after-treatment with organic compounds containing other elements
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32Polymers modified by chemical after-treatment
    • C08G65/329Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3322Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof acyclic
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08LCOMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00Applications
    • C08L2203/02Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Polyethers (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AR20030102624A 2002-07-24 2003-07-22 Aditivos a base de acidos polialquilenglicolicos AR040654A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US39813702P 2002-07-24 2002-07-24

Publications (1)

Publication Number Publication Date
AR040654A1 true AR040654A1 (es) 2005-04-13

Family

ID=31495718

Family Applications (1)

Application Number Title Priority Date Filing Date
AR20030102624A AR040654A1 (es) 2002-07-24 2003-07-22 Aditivos a base de acidos polialquilenglicolicos

Country Status (13)

Country Link
US (2) US7193031B2 (OSRAM)
EP (1) EP1526872A1 (OSRAM)
JP (2) JP4451308B2 (OSRAM)
KR (1) KR100608415B1 (OSRAM)
CN (1) CN100337689C (OSRAM)
AR (1) AR040654A1 (OSRAM)
AU (1) AU2003258518B2 (OSRAM)
BR (1) BR0313212A (OSRAM)
CA (1) CA2492775C (OSRAM)
MX (1) MXPA05000796A (OSRAM)
PL (1) PL375265A1 (OSRAM)
RU (1) RU2318004C2 (OSRAM)
WO (1) WO2004012773A1 (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
US7153829B2 (en) 2002-06-07 2006-12-26 Dyax Corp. Kallikrein-inhibitor therapies
ATE477020T1 (de) 2002-06-07 2010-08-15 Dyax Corp Prevention und verringerung von ischemia
BR0313212A (pt) * 2002-07-24 2005-06-28 Hoffmann La Roche Aditivos de ácido de polialquileno glicol
US20070020252A1 (en) * 2003-08-29 2007-01-25 Ladner Robert C Modified protease inhibitors
AU2004268145B2 (en) * 2003-08-29 2010-09-16 Takeda Pharmaceutical Company Limited Poly-PEGylated protease inhibitors
CN101132812A (zh) * 2004-03-15 2008-02-27 阿拉巴马耐科塔医药公司 Hiv进入抑制剂的聚合物基组合物和结合物
CA2567630A1 (en) * 2004-05-17 2005-11-24 Mcmaster University Biological molecule-reactive hydrophilic silicone surface
AU2005275108B2 (en) * 2004-07-16 2011-05-12 Nektar Therapeutics Conjugates of a GM-CSF moiety and a polymer
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2007022780A1 (en) * 2005-08-26 2007-03-01 Novo Nordisk A/S A method of modifying a macromolecular system
US8133707B2 (en) * 2006-01-17 2012-03-13 Enzon Pharmaceuticals, Inc. Methods of preparing activated polymers having alpha nitrogen groups
AR067537A1 (es) * 2007-07-17 2009-10-14 Hoffmann La Roche Purificacion de polipeptidos pegilados
AR067536A1 (es) 2007-07-17 2009-10-14 Hoffmann La Roche Metodo para obtener una eritropoyetina mono-pegilada en una forma sustancialmente homogenea
CA2696208A1 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
CN102159250B (zh) 2008-08-11 2014-08-06 尼克塔治疗公司 多臂的聚合烷酸酯偶联物
CA2744235A1 (en) 2009-01-06 2010-07-15 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
PL2521568T3 (pl) 2010-01-06 2019-03-29 Dyax Corp. Białka wiążące kalikreinę osocza
US10040761B2 (en) * 2010-06-25 2018-08-07 Nof Corporation Branched hetero polyethylene glycol and intermediate
US10894087B2 (en) 2010-12-22 2021-01-19 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds
US20130331443A1 (en) 2010-12-22 2013-12-12 Nektar Therapeutics Multi-arm polymeric prodrug conjugates of taxane-based compounds
KR102502293B1 (ko) 2011-01-06 2023-02-21 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 결합 단백질
CA2908238C (en) 2012-04-03 2023-01-10 Schindler, William Succinimide-activated nitroxyl compounds and methods for the use thereof for nitroxylation of proteins
CN102816227A (zh) * 2012-08-30 2012-12-12 深圳赛保尔生物药业有限公司 回收促红细胞生成素的方法
WO2014145755A1 (en) 2013-03-15 2014-09-18 Sangart, Inc. Polyalkylene oxide valerate hemoglobin conjugates
KR20230109785A (ko) 2014-03-27 2023-07-20 다케다 파머수티컬 컴패니 리미티드 당뇨병성 황반 부종의 치료를 위한 조성물 및 방법
WO2017100679A1 (en) 2015-12-11 2017-06-15 Dyax Corp. Plasma kallikrein inhibitors and uses thereof for treating hereditary angioedema attack
WO2020203583A1 (ja) * 2019-03-29 2020-10-08 日油株式会社 末端カルボキシル基含有ポリエチレングリコールの製造方法および活性化ポリエチレングリコールの製造方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5849450B2 (ja) * 1975-07-09 1983-11-04 株式会社日立製作所 スイリヨクシキカプセルユソウソウチノ ボウシクホウ
EP0206448B1 (en) * 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
JP2531661B2 (ja) 1987-02-25 1996-09-04 味の素株式会社 酸素運搬剤
US5595732A (en) 1991-03-25 1997-01-21 Hoffmann-La Roche Inc. Polyethylene-protein conjugates
US5382657A (en) * 1992-08-26 1995-01-17 Hoffmann-La Roche Inc. Peg-interferon conjugates
AU691225B2 (en) * 1993-11-10 1998-05-14 Schering Corporation Improved interferon polymer conjugates
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
TW517067B (en) 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
DK0957929T3 (da) * 1996-10-25 2006-07-03 Gilead Sciences Inc Vaskulær endotelial vækstfaktor (VEGF) nukleinsyreligandkomplekser
EP1157037B1 (en) 1999-01-29 2003-07-30 F. Hoffmann-La Roche Ag Gcsf conjugates
JP2000256211A (ja) 1999-03-02 2000-09-19 Schering Plough Corp Hiv治療薬
CZ299516B6 (cs) 1999-07-02 2008-08-20 F. Hoffmann-La Roche Ag Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem
CA2386762C (en) 1999-10-08 2009-06-16 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
DK1259562T3 (da) * 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
DE60144439D1 (de) * 2000-12-20 2011-05-26 Hoffmann La Roche Konjugate von erythropoietin (epo) mit polyethylenglykol (peg)
BR0313212A (pt) * 2002-07-24 2005-06-28 Hoffmann La Roche Aditivos de ácido de polialquileno glicol

Also Published As

Publication number Publication date
CN100337689C (zh) 2007-09-19
MXPA05000796A (es) 2005-04-19
JP2009062516A (ja) 2009-03-26
JP4451308B2 (ja) 2010-04-14
CN1671422A (zh) 2005-09-21
WO2004012773A1 (en) 2004-02-12
CA2492775A1 (en) 2004-02-12
JP2006502250A (ja) 2006-01-19
BR0313212A (pt) 2005-06-28
RU2318004C2 (ru) 2008-02-27
KR20050025663A (ko) 2005-03-14
US7193031B2 (en) 2007-03-20
US20060167218A1 (en) 2006-07-27
AU2003258518B2 (en) 2007-01-18
US20040106747A1 (en) 2004-06-03
EP1526872A1 (en) 2005-05-04
US7504477B2 (en) 2009-03-17
CA2492775C (en) 2011-06-21
KR100608415B1 (ko) 2006-08-02
RU2005105580A (ru) 2006-01-20
PL375265A1 (en) 2005-11-28
AU2003258518A1 (en) 2004-02-23
JP5112203B2 (ja) 2013-01-09

Similar Documents

Publication Publication Date Title
AR040654A1 (es) Aditivos a base de acidos polialquilenglicolicos
ES2529574T3 (es) Vehículo de administración semisólido y composiciones farmacéuticas
RU2008149932A (ru) Высокомолекулярный конъюгат подофиллотоксинов
ES2600729T3 (es) Conjugados de polímeros hiperramificados a través de enlazante escindible no enzimático
CA2671676A1 (en) Von willebrand factor-and factor viii-polymer conjugates having a releasable linkage
BR0313876B1 (pt) uso de uma mistura, e, composições de combustível e de solvente
ATE462745T1 (de) Aromatsiche polycarbonatzusammensetzung und hohlbehälter daraus
NI201200051A (es) Nuevos maitansinoides y el uso de dichos maitansonoides para preparar conjugados con un anticuerpo.
AR011157A1 (es) Arilsulfonamidas y analogos, procedimientos para su obtencion, composicion farmaceutica y el uso de dichos compuestos para preparar medicamentos
ATE450311T1 (de) Tensidgemisch enthaltend kurzkettige sowie langkettige komponenten
BRPI0407384A (pt) piridinas-triazóis como compostos antiinflamatórios
EP2338333A3 (en) Glycopegylation methods and proteins/peptides produced by the methods
MX2008001706A (es) Conjugados de una porcion g-csf y un polimero.
CY1114887T1 (el) Συνθεσεις και μεθοδοι παρασκευης συνθεσης
IL189632A0 (en) Methods for preparing polymers having terminal amine groups
EA200700312A1 (ru) Композиции для доставки лекарственных средств с высокой водорастворимостью
CR10234A (es) Procedimiento para preparar conjugados de polietilenglicol solubles en agua de inmunosupresores de macrolidos
EA200700435A1 (ru) Рентгеноконтрастные полимерные стенты
ATE53860T1 (de) Kraftstoffgemisch.
PE20110001A1 (es) Derivados de taxanos como agentes citotoxicos
ATE422163T1 (de) Absorbierbare alpha-cyanacrylat-zusammensetzungen
RU2009147217A (ru) Новые противоопухолевые соединения
ATE490986T1 (de) Polymer, vernetztes polymer, zusammensetzung für ein feststoffpolymer-elektrolyt, feststoffpolymer-elektrolyt und klebstoffzusammensetzung
ATE491475T1 (de) Konjugate enthaltend gm-csf und ein polymer
CY1109444T1 (el) Φαρμακευτικη συνθεση που περιεχει κυκλικα αναλογα σωματοστατινης

Legal Events

Date Code Title Description
FA Abandonment or withdrawal